Skin condition improver

Abstract

The present invention relates to compositions, preferably for use in treatment methods for improving or preventing one or more undesirable skin conditions. Furthermore, the present invention relates to cosmetic and / or dermatological preparations comprising such compositions.

Description

[Technical Field]

[0001] The present invention relates to a composition comprising an avenanthramide and / or a polyalkylene glycol derivative and an oil body. One aspect of the present invention relates to such a composition used in a treatment method for improving or preventing one or more undesirable skin conditions. The present invention further relates to a cosmetic and / or dermatological preparation comprising such a composition. [Background technology]

[0002] Thin, dry skin, which exhibits intensified and undesirable clinical symptoms such as excoriation, lichenification and scaling, is associated with skin aging as well as several skin diseases.

[0003] Scratching can be caused by excoriation, typically associated with acne breakouts during adolescence, or by other skin conditions such as keratosis pilaris, psoriasis, and eczema. Scratching describes some skin damage or peeling caused, for example, by excessive skin care.

[0004] Lichenification describes a skin condition involving acanthosis nigricans, characterized by thickening of the skin, typically noticeable by sight and touch, often accompanied by characteristic skin markings and / or exaggerated normal skin lines.

[0005] Scaling describes the abnormal shedding or buildup of the top layer of skin (the stratum corneum). Scaling is often associated with dry skin disorders.

[0006] Skin may become prone to scaling, for example, due to excessive dryness. The physiological mechanism that moisturizes the skin and thus prevents scaling is the production of fat. However, with increasing age, the use of, for example, soaps, shampoos, perfumes, or disinfectants, and contact with hot water and dry air conditions, for example, caused by indoor heating, the skin may become dry, rough, and begin to scale. In general, substances that cause degreasing and thus drying of the skin appear to promote the development of undesirable clinical symptoms, such as excoriation, lichenification, and dry skin (e.g., scaling).

[0007] US Patent No. 5,929,999 describes the use of polyethylene glycol esters and / or polyethylene glycol ethers in the treatment of itchy skin and scalp conditions.

[0008] Patent document 2 describes cosmetic and / or dermatological preparations containing polyethylene glycol esters and / or polyethylene glycol ethers for moisturizing the skin and delaying or preventing the skin from drying out.

[0009] Patent document 3 relates to the use of anthranilic acid amide as a cosmetic preparation for inhibiting substance P-induced release of histamine. It has been reported that the reduction in histamine release improves skin itching, skin pain and redness.

[0010] However, there is a need for additional substances and cosmetic and / or dermatological preparations that have increased effectiveness in improving or preventing undesirable skin conditions.

[0011] In the search for suitable agents, it must be considered that the substances used should be toxicologically acceptable, well tolerated by the skin, stable (especially in conventional cosmetic and / or dermatological formulations), and preferably have the lowest possible inherent odor and the lowest possible inherent color, and should be inexpensive to prepare. [Prior art documents] [Patent documents]

[0012] [Patent Document 1] International Publication No. 2016 / 207084(A1) [Patent Document 2] U.S. Patent Application Publication No. 2010 / 150854(A1) [Patent Document 3] German Patent Application Publication No. 102 54 872(A1) Summary of the Invention [Means for solving the problem]

[0013] It was therefore an object of the present invention to develop a stable, cost-effective product with skin condition improving properties, such skin conditions preferably including or consisting of scratches, lichenification and scaling associated with dry skin.

[0014] The above purpose is a) one, two, three or more compounds of formula (I)

[0015] [ka]

[0016] During the ceremony, m=0, 1, 2 or 3, p=0, 1 or 2, n=0, 1 or 2, However, if n is 1 or 2, the sum (p+m) is > 0, If n is 1 or 2, R 1 and R 2 and are both H or together form a further chemical bond, when m is 1, 2, or 3, each X is, independently of the other, OH, O-alkyl, or O-acyl; When p is 1 or 2, each Y is independently OH, O-alkyl, or O-acyl. This is a prerequisite, with the proviso that if (p+m)>0, then X or Y, at least once, is selected from the group consisting of OH and O-acyl; R 3 =H, N or alkyl It is a prerequisite that Avenanthramide, and / or one, two, three or more types of formula (II): R 1 (OCH2CHR 2 ) n OR 3 , During the ceremony, R 1 represents hydrogen or a linear or branched alkyl group having 1 to 4 carbon atoms; R 2 represents hydrogen or methyl, n represents an integer from 3 to 20. R 3 is a linear or branched alkyl or alkenyl group having 6 to 18 carbon atoms and 0, 1, 2 or 3 double bonds, or -COR 4 represents an acyl group, R 4 represents hydrogen, a linear or branched alkyl or alkenyl group having 5 to 17 carbon atoms, an alkali metal, an alkaline earth metal, or NH3; a polyalkylene glycol derivative according to and optionally, b) oil bodies; A composition according to the present invention comprising: When present, the ratio of the total amount of the avenanthramide to the total amount of the polyalkylene glycol derivative in the composition is in the range of 10:1 to 1:1000, preferably 1:1 to 1:100, particularly preferably 1:2 to 1:50, and particularly preferably 1:5 to 1:25 by weight. is solved by

[0017] The one, two, three or more avenanthramides of formula (I) in the composition according to the present invention are or comprise preferably one or two avenanthramides selected from the group consisting of avenanthramides A, B, C, D and dihydroavenanthramides A, B, C, D, respectively.

[0018] The one, two, three or more polyalkylene glycol derivatives of formula (II) in the composition according to the invention are preferably one, two, three or more polyalkylene glycol derivatives of formula (IIa) H(OCH2CH2) n OR 3 (IIa) In the formula, n represents an integer of 7 to 12, and R 3 represents a linear or branched alkyl group having 8 to 15 carbon atoms, is or comprises a polyalkylene glycol derivative according to and / or preferably one, two, three or more compounds of formula (IIb) H(OCH2CH2) n O-COR 4 (IIb) In the formula, n represents an integer of 3 to 7, and R 4 represents a linear or branched alkyl group having 7 to 11 carbon atoms, It is a polyalkylene glycol derivative.

[0019] The one, two, three or more polyalkylene glycol derivatives of formula (II) and / or (IIa) and / or (IIb) in the composition according to the invention are preferably or comprise one, two, three or more polyethylene glycol (PEG) ethers of formula (IIa) and / or one, two, three or more polyethylene glycol (PEG) esters of formula (IIb), respectively.

[0020] Polyethylene glycol ethers according to formula (II) and / or (IIa) that can be used in the composition are, for example, PEG-7 octyl ether, PEG-7 nonyl ether, PEG-7 decyl ether, PEG-7 undecyl ether, PEG-7 dodecyl ether, PEG-7 tridecyl ether, PEG-7 tetradecyl ether, PEG-8 octyl ether, PEG-8 nonyl ether, PEG-8 decyl ether, PEG-8 undecyl ether, PEG-8 dodecyl ether, PEG-8 tridecyl ether, PEG-8 tetradecyl ether, PEG-9 octyl ether, PEG-9 nonyl ether, PEG-9 decyl ether, PEG-9 undecyl ether, PEG-9 dodecyl ether, PEG-9 tridecyl ether, PEG-9 tetradecyl ether, PEG-10 octyl ether, PEG-10 nonyl ether, PEG-10 decyl ether, PEG-10 undecyl ether, PEG-10 dodecyl ether, PEG-10 tridecyl ether, PEG-10 tetradecyl ether, PEG-11 octyl ether, PEG-11 nonyl ether, PEG-11 decyl ether, PEG-11 undecyl ether, PEG-11 dodecyl ether, PEG-11 tridecyl ether, PEG-11 tetradecyl ether, PEG-12 octyl ether, PEG-12 nonyl ether, PEG-12 decyl ether, PEG-12 undecyl ether, PEG-12 dodecyl ether, PEG-12 tridecyl ether, and PEG-12 tetradecyl ether.

[0021] Preferably, the PEG ether or one or both of the PEG ethers in the composition according to the invention are polyoxyethylene (9) tridecyl ether (PEG-9 tridecyl ether) and / or polyoxyethylene lauryl ether (laureth 9).

[0022] Polyethylene glycol esters that can be used in the compositions according to formula (II) and / or (IIb) are, for example, PEG-3 octanoate, PEG-3 nonanoate, PEG-3 isononanoate, PEG-3 decanoate, PEG-3 undecanoate, PEG-3 dodecanoate, PEG-4 octanoate, PEG-4 nonanoate, PEG-4 isononanoate, PEG-4 decanoate, PEG-4 undecanoate, PEG-4 dodecanoate, PEG-5 ethylhexanoate, PEG-5 3,5,5-trimethylhexanoate, PEG-5 octanoate, PEG-5 nonanoate, PEG-5 isononanoate, PEG-5 decanoate, PEG-5 undecanoate, PEG-5 dodecanoate, PEG-6 octanoate, PEG-6 nonanoate, PEG-6 isononanoate, PEG-6 decanoate, PEG-6 undecanoate, PEG-6 dodecanoate, PEG-7 octanoate, PEG-7 nonanoate, PEG-7 isononanoate, PEG-7 decanoate, PEG-7 undecanoate, and PEG-7 dodecanoate.

[0023] Preferably, the PEG ester or one or both of the PEG esters in the composition according to the invention is PEG-5 ethylhexanoate and / or PEG-5 3,5,5-trimethylhexanoate.

[0024] It is more preferred that the one, two, three or more polyalkylene glycol derivatives are or include one, two or all of polyalkylene glycol derivatives selected from the group consisting of PEG-5 ethylhexanoate, polyoxyethylene (9) tridecyl ether and PEG-5-3,5,5-trimethylhexanoate.

[0025] Oil bodies which can be used in the compositions according to the invention are, for example, Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10, carbon atoms, such as myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl behenate, cetyl erucate, stearyl myristate, stearyl palmitate, stearyl stearate, stearyl isostearate, stearyl oleate, stearyl behenate, stearyl erucate, isostearyl myristate, isostearyl palmitate, isostearyl stearate, isostearyl stearate, Esters of linear C6 to C22 fatty acids and linear or branched C6 to C22 fatty alcohols, such as isostearyl isostearate, isostearyl oleate, isostearyl behenate, isostearyl oleate, oleyl myristate, oleyl palmitate, oleyl stearate, oleyl isostearate, oleyl oleate, oleyl behenate, oleyl erucate, behenyl myristate, behenyl stearate, behenyl isostearate, behenyl oleate, behenyl behenate, behenyl erucate, erucyl myristate, erucyl palmitate, erucyl stearate, erucyl isostearate, erucyl oleate, erucyl behenate, and erucyl erucate, are esters of linear C6 to C22 fatty acids and linear or branched C6 to C22 fatty alcohols, or esters of branched C6 to C13 carboxylic acids and linear or branched C6 to C22 fatty alcohols.Esters of linear C6-C22 fatty acids with branched alcohols, in particular 2-ethylhexanol; esters of C18-C38 alkylhydroxycarboxylic acids with linear or branched C6-C22 fatty alcohols, in particular dioctyl malate; esters of linear and / or branched fatty acids with polyhydric alcohols (such as, for example, propylene glycol, dimerdiol or tomertriol) and / or Guerbet alcohols; triglycerides based on C6-C10 fatty acids; liquid mono- / di- / triglyceride mixtures based on C6-C18 fatty acids; esters of C6-C22 fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids, in particular benzoic acid; esters of C2-C12 dicarboxylic acids with linear or branched alcohols having 1 to 22 carbon atoms or polyols having 2 to 10 carbon atoms and 2 to 6 hydroxyl groups; vegetable oils; branched primary alcohols; Also suitable are substituted cyclohexanes, linear and branched C6-C22 fatty alcohol carbonates, such as dicaprylyl carbonate (Cetiol® CC), Guerbet carbonates based on fatty alcohols having 6 to 18, preferably 8 to 10, carbon atoms, esters of benzoic acid with linear and / or branched C6-C22 alcohols (e.g. Finsorb® TN), linear or branched, symmetrical or asymmetrical dialkyl ethers having 6 to 22 carbon atoms per alkyl group, such as dicaprylyl ether (Cetiol® OE), ring-opening products of epoxidized fatty acid esters with polyols, silicone oils (cyclomethicones, silicone methicone grades, etc.) and / or aliphatic or naphthenic hydrocarbons, such as squalane, squalene or dialkylcyclohexanes.

[0026] In one embodiment of the present invention, component a) of the composition according to the invention consists of one, two, three or more avenanthramides of formula (I).

[0027] In this respect, component a) preferably consists of one specific avenanthramide. Unless otherwise specified, the above characteristics also apply to the following paragraphs.

[0028] If several different avenanthramides are present in the composition, the weight ratio of the avenanthramide having the highest weight proportion to one or all other avenanthramides is preferably 10:1 to 1:10, preferably greater than 1:1, more preferably 5:1 to 1:5, preferably greater than 1:1, particularly preferably 2:1 to 1:2, preferably greater than 1:1.

[0029] In another embodiment of the present invention, component a) of the composition according to the present invention consists of one, two, three or more polyalkylene glycol derivatives of formula (II), preferably the one, two, three or more polyalkylene glycol derivatives of formula (II) are or comprise preferably one, two, three or more polyalkylene glycol derivatives according to formula (IIa) and / or formula (IIb), respectively.

[0030] In a preferred embodiment of the invention, component a) of the composition according to the invention consists of one, two, three or more polyethylene glycol derivatives of formula (II), preferably one, two, three or more polyethylene glycol ethers of formula (IIa) and one, two, three or more polyethylene glycol esters of formula (IIb), particularly preferably one polyethylene glycol ether of formula (IIa) and one polyethylene glycol ester of formula (IIb).

[0031] If several different polyalkylene glycol derivatives are present in the composition, the weight ratio of the polyalkylene glycol derivative having the highest weight proportion to one or all other types of polyalkylene glycol derivatives is preferably 10:1 to 1:10, preferably more than 1:1, more preferably 5:1 to 1:5, preferably more than 1:1, particularly preferably 2:1 to 1:2, preferably more than 1:1.

[0032] The above ratios apply appropriately and are also preferred when several different polyethylene glycol derivatives, several different polyethylene glycol ethers and / or several different polyethylene glycol esters are present in the composition.

[0033] In yet another embodiment of the present invention, component a) of the composition according to the invention consists of one, two, three or more avenanthramides of formula (I) and one, two, three or more polyalkylene glycol derivatives of formula (II), preferably of formula (IIa) and / or formula (IIb).

[0034] It is particularly preferred that component a) consists of one avenanthramide of formula (I) and two polyalkylene glycol derivatives of formula (II).

[0035] Furthermore, component a) consists of one avenanthramide of formula (I), one PEG ester and one PEG ether, preferably In the PEG ester, the number of C atoms in the polyethylene glycol moiety is 3 to 7 and / or the number of C atoms in the ester moiety is 3 to 5, and / or In PEG ethers, the number of C-atoms in the polyethylene glycol moiety is 7 to 11 and / or the number of C-atoms in the ether moiety is 11 to 15. is particularly preferred.

[0036] Preferably, one, two or all of the polyalkylene glycol derivatives are selected from the group consisting of PEG-5 ethylhexanoate, polyoxyethylene (9) tridecyl ether and PEG-5-3,5,5-trimethylhexanoate.

[0037] It is particularly preferred if component a) comprises or consists of dihydroavenanthramide D, polyoxyethylene (9) tridecyl ether and PEG-5 ethylhexanoate.

[0038] As mentioned above, the avenanthramide may be one specific type or several different avenanthramides, and / or the polyalkylene glycol derivative may be one specific type or several different polyethylene glycol ethers of formula (IIa) and / or one specific type or several different polyethylene glycol esters of formula (IIb). In this regard, component a) preferably consists of one specific type of avenanthramide, one specific type of polyethylene glycol ester and / or one specific type of polyethylene glycol ether. Unless otherwise specified, the above characteristics also apply to the following paragraphs.

[0039] In another embodiment of the present invention, one or the two, three or more polyalkylene glycol derivatives of the composition according to the present invention are or comprise, respectively, a polyethylene glycol ester, preferably having 3 to 7 C-atoms in the polyethylene glycol moiety and / or 3 to 5 C-atoms in the ester moiety, and / or a polyethylene glycol ether, preferably having 7 to 11 C-atoms in the polyethylene glycol moiety and / or 11 to 15 C-atoms in the ether moiety.

[0040] The term "polyethylene glycol moiety" of an ester or ether is to be understood as the part of the polyethylene glycol ester or ether that is derived from polyethylene glycol.

[0041] The term "ester moiety" is to be understood as the moiety derived from the acid of the polyethylene glycol ester which forms an ester bond with polyethylene glycol, resulting in the respective polyethylene glycol ester.

[0042] The term "ether moiety" refers to a polyethylene glycol ether It is to be understood that the polyethylene glycol ether portion originates from the compound that formed the bond and resulted in the respective polyethylene glycol ether. In yet another embodiment of the present invention, one or the avenanthramide, if present, is dihydroavenanthramide D, and / or one or more or all of the polyalkylene glycol derivatives, if present, are or comprise polyoxyethylene (9) tridecyl ether and / or polyoxyethylene lauryl ether, respectively.

[0043] In a preferred embodiment of the present invention, component a) comprises or consists of dihydroavenanthramide D and polyoxyethylene(9) tridecyl ether.

[0044] In a preferred embodiment of the present invention, component a) consists of dihydroavenanthramide D and polyoxyethylene(9) tridecyl ether.

[0045] In a preferred embodiment of the present invention, component a) comprises or consists of dihydroavenanthramide D and polyoxyethylene lauryl ether.

[0046] In a preferred embodiment of the present invention, component a) consists of dihydroavenanthramide D and polyoxyethylene lauryl ether.

[0047] In yet another embodiment of the present invention, the one, two, three or more polyalkylene glycol derivatives are or comprise one, two or all polyalkylene glycol derivatives selected from the group consisting of PEG-5 ethylhexanoate, polyoxyethylene (9) tridecyl ether and PEG-5-3,5,5-trimethylhexanoate, respectively.

[0048] In one embodiment of the invention, the total amount of components a) and / or b) in the composition, if present, is sufficient to improve or prevent one or more undesirable skin conditions, preferably one or more conditions selected from the group consisting of scratching, lichenification and scaling associated with dry skin.

[0049] For the purposes of the present invention, "skin" is in particular the organ that covers the outside of the human body and consists of the epidermis, dermis and subcutaneous tissue. Preferably, for the purposes of the present invention, the lining and / or outer layer of internal organs, such as the mucous membrane, periosteum, fibrovascular tissue and retina, are not "skin".

[0050] The presence of polyalkylene glycol esters, particularly polyethylene glycol esters and polyethylene glycol ethers, in such compositions has surprisingly been shown to reduce clinical symptoms associated with dry skin, such as scaling, scarring, and lichenification (see Example 2).

[0051] Even more surprisingly, the combination of avenanthramide with polyalkylene glycol esters, particularly polyethylene glycol esters and polyethylene glycol ethers, in such compositions shows enhanced reduction of clinical symptoms associated with dry skin, such as scaling, scarring, and lichenification (see Example 3), an effect that has not previously been described for avenanthramide.

[0052] In another embodiment of the present invention, the composition according to the present invention may be used in a method of treatment for improving or preventing one or more undesirable skin conditions, preferably one or more conditions selected from the group consisting of scarring, lichenification and scaling associated with dry skin.

[0053] Yet another aspect of the present invention relates to cosmetic and / or dermatological preparations comprising compositions according to the present invention, such compositions being present in a total amount sufficient to improve or prevent one or more undesirable skin conditions, preferably one, two or more conditions selected from the group consisting of scarring, lichenification and scaling associated with dry skin.

[0054] For the purposes of the present invention, a "cosmetic" preparation is a preparation that is suitable for topical application to human skin, in particular to achieve a cosmetic effect. A "dermatological preparation" is a preparation that is suitable for topical application to human skin, in particular to achieve a pharmaceutical effect, in particular to alleviate or treat a disease, in particular a skin condition.

[0055] Surprisingly, it has also been found that compositions according to the invention containing polyalkylene glycol derivatives have excellent solubilizing properties for further added lipophilic substances or mixtures of substances that are only moderately water-soluble, such as, for example, balms, antidandruff agents, antiacne agents or substances that regenerate the skin barrier. In particular, the very good solubility-mediating properties of the compositions according to the invention for other active ingredients, such as fatty oils, fatty acids, ceramides, pseudoceramides, sterols, phytosterols or hydrocarbons, make these active ingredients ideally suited for use in cosmetic and dermatological preparations to improve or prevent one or more undesirable skin conditions, in particular those selected from the group consisting of excoriation, lichenification and scaling associated with dry skin.

[0056] In one embodiment of the present invention, the cosmetic and / or dermatological preparation is an oil-in-water (o / w) emulsion, preferably an oil-in-water two-phase system or a shampoo.

[0057] In another embodiment of the invention, the total amount of polyalkylene glycol derivatives, when present in the cosmetic and / or dermatological composition according to the invention, represents 0.1 to 5.0% by weight, preferably 0.5 to 2.5% by weight of the preparation.

[0058] In yet another embodiment of the present invention, the total amount of avenanthramides, when present in the cosmetic and / or dermatological composition according to the invention, represents 0.005 to 1.0% by weight of the preparation, preferably 0.01 to 1.0% by weight, preferably 0.05 to 1.0% by weight, preferably 0.005 to 0.20% by weight, preferably 0.01 to 0.20% by weight, 0.02 to 0.20% by weight.

[0059] In another embodiment of the invention, the cosmetic and / or dermatological preparation further comprises one or more moderately water-soluble active ingredients selected from the group consisting of fragrances, perfume oils, aromatic substances, fragrances, fatty oils, phytosterols, anti-acne active ingredients, anti-dandruff active ingredients, antibacterial active ingredients, antiseptics, antiperspirants, anti-irritants, itch-relieving active ingredients, cooling active ingredients, antioxidants, UV filters, anti-aging active ingredients, skin whitening and skin tanning active ingredients, skin moisturizers, osmolality regulators, insect repellents, enzyme inhibitors, odor absorbers, dyes.

[0060] In yet another embodiment of the present invention, the cosmetic and / or dermatological preparations can be used in a treatment method for improving or preventing one or more undesirable skin conditions, preferably one, two or more conditions selected from the group consisting of scarring, lichenification and scaling associated with dry skin.

[0061] The compounds described herein are to be understood as the respective compounds, their stereoisomers and / or their respective salts.

[0062] Preferred embodiments and further aspects of the present invention are set forth in the appended claims and the following examples, which are not intended to limit the scope of the invention. [Example]

[0063] Example 1.1 (Reference example)

[0064] [Table 1]

[0065] Example 1.2 (Reference example)

[0066] [Table 2]

[0067] Example 1.3 (Reference example)

[0068] [Table 3]

[0069] Example 1.4 Formulation Examples 1-14 Preparations (preparations) containing the compositions according to the present invention that have a skin condition improving effect 1: Skin whitening day cream o / w 2: Shampoo every day 3: After sun balm 4: Deodorizing body spray 5: Sunscreen lotion (o / w, broadband protection) 6: Without Night Cream 7. Anti-dandruff shampoo 8: Anti-aging and barrier repair cream 9: Antiperspirant / deodorant roll-on 10: Re-greasing liquid soap (refatting liquid soap) 11: Refreshing Hair Conditioning Spray 12: Shaving cream oil 13: Hair conditioner with UV-B / UV-A protection, rinse-off 14: Hair conditioner, leave-on

[0070] [Table 4] TIFF0007759687000006.tif240170 TIFF0007759687000007.tif245170 TIFF0007759687000008.tif250170 TIFF0007759687000009.tif249170

[0071] Example 2: In vivo application Two formulations according to the invention were tested on 40 subjects (aged 35-80 years) with visually dry skin. The double-blind study was carried out for 4 weeks. The subjects used composition A and composition B for two consecutive weeks.

[0072] [Table 5]

[0073] The parameters of scaling, scarring, and lichenification were measured for compositions A and B, respectively, before the test (baseline) and two weeks after application. A 10-point ordinal scale ranging from 0 = none to 9 = severe was applied to evaluate the parameters. The reduction in the score for preparation A or B, respectively, was evaluated as the reduction in the score between the baseline and two-week measurements, as shown in the table below.

[0074] [Table 6]

[0075] Formulation A, containing trideceth-9 and PEG-5 ethylhexanoate, reduced clinical symptoms associated with dry skin, such as scaling, excoriation, and lichenification, by 22.5%, 20.4%, and 20.3%, respectively (average values ​​for 40 subjects).

[0076] Formulation B, containing dihydroavenanthramide D, trideceth-9, and PEG-5 ethylhexanoate, demonstrated enhanced reductions of clinical symptoms associated with dry skin, such as scaling, excoriation, and lichenification, by 47.2%, 48.5%, and 45.7%, respectively (average values ​​for 40 subjects).

[0077] Example 3: In vivo application Three shampoo formulations were tested on 20 subjects (16 females, 4 males; mean age: 48.9 years) with scalp scaling symptoms.

[0078] [Table 7]

[0079] The study was carried out in a temperature- and humidity-controlled room (24±2°C; 50+10% RU). Subjects underwent a 7-day washout period during which they used a standardized washout shampoo without actives.

[0080] Each volunteer then, according to a randomization chart, tested shampoo 1, 2, or 3. The products were filled in unlabeled containers that did not provide any information regarding the treatment.

[0081] At baseline, volunteers were clinically examined for the degree of scaling (T0). After the baseline evaluation, volunteers were given a shampoo (active or placebo) based on a randomization chart. Each volunteer used their assigned shampoo three times a week.

[0082] At the end of treatment (T7), clinical evaluation was performed for reduction in skin scaling.

[0083] [Table 8]

[0084] No reduction in scaling was observed in subjects treated with Shampoo 1 or 3. However, patients treated with Shampoo 2 showed a 22.2% reduction in scaling. This was particularly surprising because Shampoo 2 contained fewer of each single substance than Shampoo 1 or Shampoo 3. Furthermore, this finding was unexpected because the sum of dihydroavenanthramide D, trideceth-9, and PEG-5 ethylhexanoate in Shampoo 2 was even lower than the sum of trideceth-9 and PEG-5 ethylhexanoate in Shampoo 3.

Claims

1. a) dihydroavenanthramide D, Polyoxyethylene (9) tridecyl ether, and PEG-5 ethylhexanoate, Including, arbitrarily b) oil bodies; 1. A composition for improving or preventing one or more undesirable skin conditions, optionally comprising: the ratio of the total amount of dihydroavenanthramide D to the total amount of polyoxyethylene (9) tridecyl ether and PEG-5 ethylhexanoate in the composition is in the range of 10:1 to 1:1000 by weight; The composition, wherein the total amount of components a) and b) in the composition is sufficient to improve or prevent the one or more undesirable skin conditions, wherein the one or more undesirable skin conditions are one, two or more conditions selected from the group consisting of scratching, lichenification and scaling associated with dry skin.

2. 2. The composition according to claim 1, wherein the ratio of the total amount of dihydroavenanthramide D to the total amount of polyoxyethylene (9) tridecyl ether and PEG-5 ethylhexanoate in the composition is in the range of 1:1 to 1:100 by weight.

3. A composition described in any one of claims 1 to 2 for use in a treatment method for improving or preventing one or more undesirable skin conditions.

4. Cosmetic and / or dermatological preparations comprising a composition according to any one of claims 1 to 2.

5. 5. The cosmetic and / or dermatological preparation of claim 4, wherein said compositions are present in a total amount sufficient to improve or prevent said one or more undesirable skin conditions.

6. Cosmetic and / or dermatological preparation according to any one of claims 4 to 5, wherein the preparation is an oil-in-water (o / w) emulsion.

7. 7. The cosmetic and / or dermatological preparation according to claim 6, which is a shampoo.

8. 8. Cosmetic and / or dermatological preparation according to claim 4, wherein the total amount of polyoxyethylene (9) tridecyl ether and PEG-5 ethylhexanoate represents from 0.1 to 5.0% by weight of the preparation.

9. 9. Cosmetic and / or dermatological preparation according to claim 8, wherein the total amount of polyoxyethylene (9) tridecyl ether and PEG-5 ethylhexanoate represents from 0.5 to 2.5% by weight of the preparation.

10. 10. Cosmetic and / or dermatological preparation according to any one of claims 4 to 9, wherein the total amount of dihydroavenanthramide D represents 0.005 to 1.0% by weight of the preparation.

11. 11. Cosmetic and / or dermatological preparation according to claim 10, wherein the total amount of dihydroavenanthramide D represents 0.01 to 1.0% by weight of the preparation.

12. 12. The cosmetic and / or dermatological preparation according to any one of claims 4 to 11, wherein the preparation further comprises one or more moderately water-soluble active ingredients selected from the group consisting of odoriferous substances, perfume oils, fragrance substances, aromatic bodies, fatty oils, fatty acids, waxes, ceramides, pseudoceramides, sterols, phytosterols, anti-acne active ingredients, anti-dandruff active ingredients, antibacterial active ingredients, antiseptics, antiperspirants, anti-irritants, anti-itch active ingredients, cooling active ingredients, antioxidants, UV filters, anti-ageing active ingredients, skin whitening and skin tanning active ingredients, skin moisture regulators, osmolality regulators, insect repellents, enzyme inhibitors, odor absorbers, dyes.

Images